A journey through the history of PEGylated drug delivery nanocarriers

被引:17
作者
Lopez-Estevez, Ana M. [1 ,2 ,3 ]
Gref, Ruxandra [4 ]
Alonso, Maria J. [1 ,2 ,3 ]
机构
[1] CIMUS Res Inst, Santiago De Compostela, Spain
[2] IDIS Res Inst, Santiago De Compostela, Spain
[3] Univ Santiago de Compostela, Dept Pharm & Pharmaceut Technol, Santiago De Compostela, Spain
[4] Univ Paris Saclay, Inst Mol Sci, CNRS, ISMO UMR 8216, Orsay, France
关键词
Nanoparticles; PEGylation; Drug targeting; NANOPARTICLE DIFFUSION; PEG NANOPARTICLES; MALIGNANT GLIOMA; IN-VIVO; BRAIN; MUCUS; LOCALIZATION; NANOSPHERES; PARTICLES; TRANSPORT;
D O I
10.1007/s13346-024-01608-8
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
This note aims to inspire through providing a personal view of the development and potential Drug Delivery Nanocarriers functionalized with polythyleneglycol (PEG). This polymer has been used extensively in Pharmaceutical Technology in a variety of compositions, including polyethylene oxide (PEO)-based surfactants. However, the concept of PEGylation, which started in the 70's, differs from the functionality of a surfactant, already discloses in the 50's. Here, we strictly adhere to the biological functionality of PEGylated nanocarriers intended to have a reduced interaction with proteins and, therefore, modify their biodistribution as well as facilitate their diffusion across mucus and other biological barriers. We analyze how this concept has evolved over the years and the benefit obtained so far in terms of marketed nanomedicines and provide the readers with a prospect view of the topic.
引用
收藏
页码:2026 / 2031
页数:6
相关论文
共 34 条
[1]   Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 [J].
Aktas, Y ;
Yemisci, M ;
Andrieux, K ;
Gürsoy, RN ;
Alonso, MJ ;
Fernandez-Megia, E ;
Novoa-Carballal, R ;
Quiñoá, E ;
Riguera, R ;
Sargon, MF ;
Çelik, HH ;
Demir, AS ;
Hincal, AA ;
Dalkara, T ;
Çapan, Y ;
Couvreur, P .
BIOCONJUGATE CHEMISTRY, 2005, 16 (06) :1503-1511
[2]   Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting [J].
Brigger, I ;
Morizet, J ;
Aubert, G ;
Chacun, H ;
Terrier-Lacombe, MJ ;
Couvreur, P ;
Vassal, G .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :928-936
[3]   Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat [J].
Calvo, P ;
Gouritin, B ;
Villarroya, H ;
Eclancher, F ;
Giannavola, C ;
Klein, C ;
Andreux, JP ;
Couvreur, P .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 15 (08) :1317-1326
[4]   Commentary - The origin of pegnology [J].
Davis, FF .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) :457-458
[5]   The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa [J].
De Campos, AM ;
Sánchez, A ;
Gref, R ;
Calvo, P ;
Alonso, MJ .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 20 (01) :73-81
[6]  
GABIZON A, 1994, CANCER RES, V54, P987
[7]  
GABIZON AA, 1992, CANCER RES, V52, P891
[8]   PEGylated therapeutics in the clinic [J].
Gao, Yongsheng ;
Joshi, Maithili ;
Zhao, Zongmin ;
Mitragotri, Samir .
BIOENGINEERING & TRANSLATIONAL MEDICINE, 2024, 9 (01)
[9]   'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG):: influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption [J].
Gref, R ;
Lück, M ;
Quellec, P ;
Marchand, M ;
Dellacherie, E ;
Harnisch, S ;
Blunk, T ;
Müller, RH .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2000, 18 (3-4) :301-313
[10]   THE CONTROLLED INTRAVENOUS DELIVERY OF DRUGS USING PEG-COATED STERICALLY STABILIZED NANOSPHERES [J].
GREF, R ;
DOMB, A ;
QUELLEC, P ;
BLUNK, T ;
MULLER, RH ;
VERBAVATZ, JM ;
LANGER, R .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) :215-233